Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Bitopertin on Midazolam PK in Healthy Volunteers
NCT02019290Phase 1Withdrawn
- Sponsor
- Roche
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bitopertin in schizophrenia, sponsored by Roche. Primary endpoint: Change in plasma area under the concentration-time curve (AUC) of midazolam at Day 15. Planned start Feb 2014; status: withdrawn.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02019290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019290.